Myelosuppression in breast cancer patients receiving postoperative radiation

Authors

  • Pongsatorn Supaattagorn Radiation oncology department ,Ubonratchathani cancer center
  • Tawin Chottetanaprasith Radiation oncology department ,Ubonratchathani cancer center
  • Thanut Khuayjarernpanishk Radiation oncology department ,Ubonratchathani cancer center
  • Sirilak Ngoeiwikit Radiation oncology outpatient department ,Ubonratchathani cancer center
  • Chuenchom Songyai Radiation oncology outpatient department ,Ubonratchathani cancer center
  • Kanittha Promsumlee Radiation oncology outpatient department ,Ubonratchathani cancer center
  • Mutita Sappsarn Radiation oncology outpatient department ,Ubonratchathani cancer center

Abstract

The addition of radiation after mastectomy or breast conservative surgery in high risk breast cancer women can reduces the risk of locoregional recurrence. Weekly CBC is a routine monitor during the period of radiation. But the CBC abnormalities or bone marrow suppression is not much observed in our clinical practice. The purpose of this retrospective study was to evaluate the necessary of this routine practice. We had collected the CBC abnormalities in 122 stage I-III breast cancer patients who received postoperative radiation with or without preceding adjuvant chemotherapy in 2008. The fi nding showed that 27 % ,12.2 % and 2.4 % of patients had Hb < 10 g% , ANC < 1,500/mm3 and PLT < 100,000 /mm3 in any weeks during radiation period. The mean duration between adjuvant chemotherapy and starting date of radiation were 4 weeks and 4.8 weeks in the patients who had abnormal CBC and no abnormal CBC respectively. Most of these abnornormalities occurred in the fi rst 3 weeks of radiation. In our conclusion, routine CBC entired radiation period may not be necessary. CBC monitor in the fi rst few weeks and clinical evaluation may be suffi cient.

References

หน่วยทะเบียนมะเร็ง ศูนย์มะเร็งอุบลราชธานี. Hospital based cancer registry 2008 : 16-20.

Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy . N Engl J Med 1997 Oct 2;337(14):949-55.

Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999 May 15;353(9165):1641-8.

Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997 Oct 2;337(14):956-62.

Downloads

Published

2010-06-29

How to Cite

1.
Supaattagorn P, Chottetanaprasith T, Khuayjarernpanishk T, Ngoeiwikit S, Songyai C, Promsumlee K, Sappsarn M. Myelosuppression in breast cancer patients receiving postoperative radiation. J Thai Assn of Radiat Oncol [Internet]. 2010 Jun. 29 [cited 2024 Jul. 3];16(1):51-4. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/203516

Issue

Section

Original articles